首頁 › 直腸癌 › 密西根 › Grand Rapids
Grand Rapids, MI 的 直腸癌 臨床試驗
6 項針對 直腸癌 的研究正在 Grand Rapids（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Family Communications After Genetic Testing
招募中歡迎健康志工
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Trinity Health Grand Rapids Hospital, Grand Rapids
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
招募中歡迎健康志工
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Trinity Health Grand Rapids Hospital, Grand Rapids
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- START Midwest, Grand Rapids
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中觀察性研究
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
招募中
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Trinity Health Grand Rapids Hospital, Grand Rapids
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
招募中3 期
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
其他城市的 直腸癌 試驗
- New York City, NY17 項研究
- Boston, MA12 項研究
- Houston, TX11 項研究
- St. Louis, MO11 項研究
- Columbus, OH10 項研究
- Los Angeles, CA10 項研究
- Tampa, FL9 項研究
- Nashville, TN9 項研究
- Seattle, WA9 項研究
- Baldwin Park, CA8 項研究
- Aurora, CO8 項研究
- Salt Lake City, UT8 項研究
Grand Rapids 的其他研究
- 非小細胞肺癌44 項研究
- 大腸直腸癌40 項研究
- 癌症（所有類型）28 項研究
- 乳癌26 項研究
- 卵巢癌24 項研究
- 轉移性癌症22 項研究
- 前列腺癌19 項研究
- 子宮內膜癌18 項研究
- 胃癌18 項研究
- 胰臟癌18 項研究
- 黑色素瘤17 項研究
- 頭頸部鱗狀細胞癌15 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。